Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

January 2018, Volume 256, Issue 1, pp. 221–223
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: January 3, 2018

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

January 2018, Volume 256, Issue 1, pp. 233–235
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: January 3, 2018

Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion

December 2017, Volume 184, p.190–191
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: December 1, 2017

Comments to: Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal

Nov-Dec 2017, Volume 27, Issue 6, pp. 627 - 800, e175 - e195
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: November 13, 2017

Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial

October 2017, Volume 182, p.204–205
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: October 2, 2017

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study

October 2017, Volume 255, Issue 10, pp. 2073–2075
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: October 1, 2017

High-frequency aflibercept injections in persistent neovascular age-related macular degeneration

October 2017, Volume 255, Issue 10, pp. 2067–2068
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: October 1, 2017

Comment on “Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion”

September 2017, Volume 10, Issue 9, p.1481-1482
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: September 5, 2017

Correspondence

September 2017, Volume 37, Issue 9, p.e108–e110
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: September 1, 2017

Comments to: Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results

Jul-Aug 2017, Volume 27, Issue 4, pp. 387 - 512, e129 - e135
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: July 25, 2017

Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness

July 2017, Volume 48, Issue 7, p.528-529
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: July 5, 2017

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA

July 2017, Volume 31, Issue 7, p.1112-1113
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: July 4, 2017

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

July 2017, Volume 255, Issue 7, pp. 1455–1457
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: July 1, 2017

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

July 2017, Volume 255, Issue 7, pp. 1451–1452
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: July 1, 2017

Correspondence

Jun 2017, Volume 37, Issue 6, p. e84–e86
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: Jun 1, 2017

Correspondence

Jun 2017, Volume 37, Issue 6, p. e78–e79
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: Jun 1, 2017

Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization

May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: May 11, 2017

Comments to: Ranibizumab for persistent diabetic macular edema after bevacizumab treatment

May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: May 11, 2017

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study

May 2017, Volume 177, p.235–236
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: May 2, 2017

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion

May 2017, Volume 255, Issue 5, pp. 1043–1044
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: May 1, 2017

Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: April 24, 2017

Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab

April 2017, Volume 48, Issue 4, p.280
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: April 19, 2017

Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion

April 2017, Volume 176, p.257–258
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: April 1, 2017

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: March 28, 2017

Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion

February 2017, Volume 52, Issue 1, p.137
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Published online: February 23, 2017

Bun venit!

Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.

În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.

Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).

Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.

Analizele necesare pentru operație:

  • Hemoleucograma
  • Coagulograma
  • Glicemie
  • Uree
  • VSH
  • AST
  • ALT
  • Bilirubina totală
  • HVB
  • HVC
  • HIV
  • Consult cardiologic
  • EKG

Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.